- Home
- FOXO vs ZVSA Comparison
FOXO vs ZVSA Comparison
Compare FOXO & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXO
- ZVSA
- Stock Information
- Founded
- FOXO 2019
- ZVSA 2014
- Country
- FOXO United States
- ZVSA United States
- Employees
- FOXO N/A
- ZVSA 7
- Industry
- FOXO Retail: Computer Software & Peripheral Equipment
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- FOXO Technology
- ZVSA Health Care
- Exchange
- FOXO Nasdaq
- ZVSA Nasdaq
- Market Cap
- FOXO 2.4M
- ZVSA 2.6M
- IPO Year
- FOXO N/A
- ZVSA N/A
- Fundamental
- Price
- FOXO $0.53
- ZVSA $1.10
- Analyst Decision
- FOXO
- ZVSA Strong Buy
- Analyst Count
- FOXO 0
- ZVSA 1
- Target Price
- FOXO N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- FOXO 143.7M
- ZVSA 3.6M
- Earning Date
- FOXO 08-19-2024
- ZVSA 11-14-2024
- Dividend Yield
- FOXO N/A
- ZVSA N/A
- EPS Growth
- FOXO N/A
- ZVSA N/A
- EPS
- FOXO N/A
- ZVSA N/A
- Revenue
- FOXO $1,341,000.00
- ZVSA N/A
- Revenue This Year
- FOXO N/A
- ZVSA N/A
- Revenue Next Year
- FOXO N/A
- ZVSA N/A
- P/E Ratio
- FOXO N/A
- ZVSA N/A
- Revenue Growth
- FOXO N/A
- ZVSA N/A
- 52 Week Low
- FOXO $0.13
- ZVSA $1.04
- 52 Week High
- FOXO $1.30
- ZVSA $42.35
- Technical
- Relative Strength Index (RSI)
- FOXO 52.56
- ZVSA 32.04
- Support Level
- FOXO $0.55
- ZVSA $1.10
- Resistance Level
- FOXO $0.84
- ZVSA $1.29
- Average True Range (ATR)
- FOXO 0.27
- ZVSA 0.25
- MACD
- FOXO -0.01
- ZVSA -0.02
- Stochastic Oscillator
- FOXO 33.61
- ZVSA 3.86
About FOXO FOXO Technologies Inc.
FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. The company has two reportable business segments, FOXO Labs and FOXO Life.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.